ArticleCPT: pharmacometrics & systems pharmacology2024
Confounded exposure metrics.
Article in CPT: pharmacometrics & systems pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7.British journal of cancer · 2026Trial
- Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study.Targeted oncology · 2025Trial
- Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.CPT: pharmacometrics & systems pharmacology · 2024Trial
- Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Advanced Non-small Cell Lung Cancer.Clinical pharmacology and therapeutics · 2026Article
- Pharmaceutical Industry Perspectives on Exposure-Response Confounding in Large Molecule Therapeutics: Results From an IQ Consortium Survey.CPT: pharmacometrics & systems pharmacology · 2026Article
- Time-Dependent Bias and Prognostic Confounding in Exposure-Response Analysis of Targeted Therapies: Lessons from Sunitinib in Metastatic Renal Cancer.Clinical pharmacology and therapeutics · 2026Article
- Integration of Time-Varying Pharmacometric Modeling With Cox Regression for Time-to-Event Analysis in NONMEM.CPT: pharmacometrics & systems pharmacology · 2026Article
- Longitudinal Tumor Size and Survival Modeling for Exposure-Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer.Clinical pharmacology and therapeutics · 2026Article
- Applications of Pharmacometrics in Antibody-Drug Conjugate Development.Pharmaceutics · 2026Review
- Can evolutionary therapy be applied in non-small cell lung cancer?Scientific reports · 2026Article
- Exposure-Response Analysis for Time-to-Event Data in the Presence of Adaptive Dosing: Efficient Approaches and Pitfalls.CPT: pharmacometrics & systems pharmacology · 2026Article
- Evaluation and Mitigation of Time-Dependent Confounding Effects in Conventional Exposure-Response Analyses for Oncology Drugs.CPT: pharmacometrics & systems pharmacology · 2025Article
- Population Pharmacokinetics of Valemetostat and Exposure-Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma.Journal of clinical pharmacology · 2025Article
- Comprehensive Safety Exposure-Response Analysis to Support Ritlecitinib Dose Selection.CPT: pharmacometrics & systems pharmacology · 2025Article
- A Novel Two-Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients.Clinical pharmacology and therapeutics · 2025Article
- An exposure-safety analysis to support the dosage of the novel AKT inhibitor capivasertib.Cancer chemotherapy and pharmacology · 2025Article
- Indirect modeling of derived outcomes: Are minor prediction discrepancies a cause for concern?CPT: pharmacometrics & systems pharmacology · 2024Article
- Automated Poisson regression exposure-response analysis for binary outcomes with PoissonERM.CPT: pharmacometrics & systems pharmacology · 2024Article
- Recommendation of mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathy.CPT: pharmacometrics & systems pharmacology · 2024Article
- Confounded exposure metrics.CPT: pharmacometrics & systems pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.